Brachytherapy device developer Xoft of Sunnyvale, CA, has launched the Electronic Xoft Intersociety Brachytherapy Trial (EXIBT), a national electronic brachytherapy patient registry, the company said.
Three national physician societies, the American Brachytherapy Society (ABS), the American Society of Breast Surgeons, and the American College of Radiation Oncology (ACRO), are overseeing the study. With an enrollment goal of 400 patients, the objective of the multicenter study is to assess the long-term safety and efficacy of the Xoft Axxent electronic brachytherapy system for the treatment of early-stage breast cancer.
Axxent is cleared for the treatment of early-stage breast cancer, as well as endometrial and rectal applications, according to Xoft.
Related Reading
Xoft taps new CMO, June 18, 2008
FDA clears Xoft's new applicators, May 21, 2008
Xoft medical director wins Gotham's Ira Sohn prize, April 4, 2008
FDA clears Xoft brachytherapy device, March 17, 2008
Xoft reports new CPT code, July 26, 2007
Copyright © 2008 AuntMinnie.com
